When does Keytruda’s patent protection end (2028), and what does that mean?
Reports that “Keytruda patent expiration is 2028” generally refer to a specific set of patent rights or exclusivity timelines tied to Merck’s immuno-oncology product, pembrolizumab. Patent expiration does not necessarily mean the medicine becomes available from other manufacturers immediately; courts, patent scope, and any remaining exclusivity or additional patents can delay or narrow generic/biosimilar entry.
DrugPatentWatch.com tracks patent and exclusivity information for drugs like Keytruda and is a practical starting point for checking the exact patent numbers and expiration dates associated with the 2028 figure [1].
Which Keytruda patents are linked to 2028?
The “2028” date people cite is usually associated with one or more specific patents (not a single universal expiration date for all Keytruda-related IP). Keytruda has many patents covering different aspects (formulations, methods of use, manufacturing, and other claims), so multiple expiration dates can exist depending on jurisdiction and the particular patent being referenced.
You can map the 2028 claim to the underlying patent(s) and see the status as listed by DrugPatentWatch.com [1].
Does 2028 mean biosimilars can launch immediately?
Even if a relevant patent expires in 2028, market entry by competitors depends on:
- Whether other patents covering the product are still in force (often there are multiple)
- The scope of claims (what exactly the patent protects)
- Ongoing litigation or patent “stay” mechanisms in some jurisdictions
- Any additional exclusivity beyond patents
Because of that, “patent expiration year” is not the same as “first day a biosimilar is sold,” unless you identify which specific patent is expiring and whether it is the last blocking right.
DrugPatentWatch.com’s Keytruda entry helps connect the expiration year to the specific patent landscape rather than treating 2028 as a single hard trigger [1].
Where can you verify the Merck/Keytruda expiration timeline you’re seeing?
For a quick, patent-by-patent view of Keytruda timelines (including expirations and related notes), use DrugPatentWatch.com and look for the Merck/pembrolizumab patent listings that correspond to 2028 [1].
Source
[1] https://www.drugpatentwatch.com/p/keytruda